Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jennifer A,Whitty

第一单位： Norwich Medical School, University of East Anglia, Norwich, UK jennifer.whitty@uea.ac.uk.

作者： Jennifer A,Whitty ^[1] ; Jenny,Rankin ^[2] ; Dina,Visca ^[3] ; Vicky,Tsipouri ^[4] ; Letizia,Mori ^[5] ; Lisa,Spencer ^[6] ; Huzaifa,Adamali ^[5] ; Toby M,Maher ^[6] ; Nicholas S,Hopkinson ^[5] ; Surinder S,Birring ^[6] ; Morag,Farquhar ^[7] ; Athol U,Wells ^[8] ; Piersante,Sestini ^[6] ; Elisabetta A,Renzoni ^[6]

作者单位： Norwich Medical School, University of East Anglia, Norwich, UK jennifer.whitty@uea.ac.uk. ^[1] Collaboration for Leadership in Applied Health Research and Care (CLAHRC), East of England, UK. ^[2] Norwich Medical School, University of East Anglia, Norwich, UK. ^[3] Division of Pulmonary Rehabilitation, Istituti Clinic Scientifici Maugeri, IRCCS, Tradate, Italy. ^[4] Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK. ^[5] National Heart and Lung Institute, Imperial College London, London, UK. ^[6] Liverpool Interstitial Lung Disease Service, Aintree Chest Centre, University Hospital Aintree, Liverpool, UK. ^[7] Bristol Interstitial Lung Disease (BILD) Service, Southmead Hospital, Bristol, UK. ^[8] Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences nd Medicine, King's College London, London, UK. ^[9] School of Health Sciences, University of East Anglia, Norwich, UK. ^[10] Dept of Respiratory Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. ^[11]